阿比特龙与食物同服提升药代动力学暴露:治疗药物监测真实世界数据
本研究在32例可评估的前列腺癌患者中开展治疗药物监测,20例(63%)在治疗期间某时点血药谷浓度低于8.4 ng/mL;推荐与轻食或点心同服后,谷浓度由6.9 ng/mL升至27 ng/mL(p<0.001),未见额外毒性,28例(87.5%)达到充分暴露。
要点
- 固定剂量空腹服药下部分患者谷浓度不达标,可按治疗药物监测结果干预。
- 谷浓度低于8.4 ng/mL且毒性可接受时,建议与轻食或点心同服阿比特龙。
- 食物干预后谷浓度显著升高且未增加毒性,为低成本优化暴露的手段。
核心结论
- 阿比特龙治疗药物监测在临床实践中可行,与食物同服可显著提高谷浓度,为低暴露患者提供成本中性的优化机会。
研究设计与样本
- 前瞻性治疗药物监测项目,纳入开始常规阿比特龙治疗(改良空腹状态)的患者,共32例可评估。
- 于治疗开始后第4、8、12周及此后每12周进行药代动力学分析。
主要发现
- 20例(63%)患者在治疗期间某时点谷浓度低于8.4 ng/mL。
- 推荐与食物同服后,谷浓度由6.9 ng/mL升至27 ng/mL(p<0.001),未出现额外毒性。
- 该干预使28例(87.5%)患者达到充分暴露。
关键数值与推荐
- 目标谷浓度阈值为8.4 ng/mL,低于该值且毒性可接受时推荐药代动力学引导干预。
- 干预第一步为阿比特龙与轻食或点心同服。
临床怎么用
- 对接受固定剂量阿比特龙治疗的患者可行治疗药物监测,谷浓度不达标者优先尝试与轻食或点心同服以提高暴露。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: Abiraterone acetate is approved for the treatment of metastatic prostate cancer. At the currently used fixed dose of 1000 mg once daily in modified fasting state, 40% of patients do not reach the efficacy threshold of a minimum plasma concentration (Cmin) ≥ 8.4 ng/mL and are thereby at risk of decreased treatment efficacy. This study aims to evaluate whether pharmacokinetically (PK) guided abiraterone acetate dosing with a food intervention is feasible and results in an increased percentage of patients with concentrations above the target. METHODS: Patients starting regular treatment with abiraterone acetate in modified fasting state were included. Pharmacokinetic analysis was performed 4, 8 and 12 weeks after start of treatment and every 12 weeks thereafter. In case of Cmin < 8.4 ng/mL and acceptable toxicity, a PK-guided intervention was recommended. The first step was concomitant intake of abiraterone acetate with a light meal or a snack. RESULTS: In total, 32 evaluable patients were included, of which 20 patients (63%) had a Cmin < 8.4 ng/mL at a certain time point during treatment. These patients were recommended to take abiraterone acetate concomitantly with food, after which Cmin increased from 6.9 ng/mL to 27 ng/mL (p < 0.001) without additional toxicities. This intervention led to adequate exposure in 28 patients (87.5%). CONCLUSION: Therapeutic drug monitoring of abiraterone was applied in clinical practice and proved to be feasible. Concomitant intake with food resulted in a significant increase in Cmin and offers a cost-neutral opportunity to optimise exposure in patients with low Cmin.
引用
- Groenland SL, van Nuland M, Bergman AM, et al. Concomitant intake of abiraterone acetate and food to increase pharmacokinetic exposure: real life data from a therapeutic drug monitoring programme. Eur J Cancer. 2020. PMID: 32172196. doi:10.1016/j.ejca.2020.02.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。